We are live on ! Find out more
GPCR icon

Structure Therapeutics

156 hedge funds and large institutions have $1.58B invested in Structure Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $30.2M | Put options by funds: $19.7M

40% more capital invested

Capital invested by funds: $1.13B → $1.58B (+$449M)

21% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 48

3.03% more ownership

Funds ownership: 95.31%98.33% (+3%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

9% less funds holding

Funds holding: 172156 (-16)

41% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 37

Holders
156
Holders Change
-16
Holders Change %
-9.3%
% of All Funds
2.05%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
22
Increased
58
Reduced
48
Closed
37
Calls
$30.2M
Puts
$19.7M
Net Calls
+$10.6M
Net Calls Change
+$8.63M
Name Holding Trade Value Shares
Change
Change in
Stake
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$12.9M +$9.19M +461,553 New
Citadel Advisors
27
Citadel Advisors
Florida
$12.4M -$17.6M -884,679 -67%
Invesco
28
Invesco
Georgia
$12.4M +$382K +19,189 +5%
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$11.4M +$1.55M +77,700 +24%
DM
30
Deerfield Management
New York
$10.5M
PBA
31
Paradigm Biocapital Advisors
New York
$10.4M +$7.43M +372,869 New
NCM
32
Nantahala Capital Management
Connecticut
$10.3M +$3.98M +200,000 +119%
ACH
33
ArrowMark Colorado Holdings
Colorado
$9.05M +$483K +24,229 +8%
BG
34
Bellevue Group
Switzerland
$8.84M -$651K -32,670 -9%
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$8.1M -$1.26M -63,475 -18%
BlackRock
36
BlackRock
New York
$7.39M +$410K +20,604 +8%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$6.98M +$4.25M +213,199 +591%
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$6.86M +$4.88M +244,848 New
RAM
39
Readystate Asset Management
Illinois
$6.64M +$1.17M +58,576 +33%
HS
40
HighVista Strategies
Massachusetts
$6.61M +$2.98M +149,615 +173%
SAM
41
Sectoral Asset Management
Quebec, Canada
$6.21M +$3.4M +170,503 +332%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$5.98M +$2.74M +137,806 +182%
UBS Group
43
UBS Group
Switzerland
$5.83M +$1.1M +55,111 +36%
MIM
44
Monashee Investment Management
Massachusetts
$5.6M -$4.58M -230,000 -53%
PC
45
Pier Capital
Connecticut
$5.53M -$19.3K -969 -0.5%
FLAM
46
First Light Asset Management
Minnesota
$5.53M +$1.5M +75,124 +61%
Two Sigma Investments
47
Two Sigma Investments
New York
$5.12M +$3.64M +182,911 New
RPAM
48
Rhenman & Partners Asset Management
Sweden
$5.04M +$896K +45,000 +33%
SFM
49
Sphera Funds Management
Israel
$4.87M +$1.55M +78,000 +81%
JFG
50
Jefferies Financial Group
New York
$4.77M +$3.39M +170,345 New

GPCR Hedge Fund Activity: Q3 2025 in Review

156 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q3 2025, worth a combined $1.58B — up 40% from $1.13B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of GPCR and 22 opened new positions — a net loss of 15 holders — while 48 trimmed existing stakes and 58 added.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $103M. The largest seller was Capital International Investors, exiting entirely with an estimated $33.6M sold.

  • 156 institutional investors held Structure Therapeutics (GPCR) as of Q3 2025, down from 172 in Q2 2025.
  • Funds reported $1.58B of Structure Therapeutics stock for Q3 2025, up 40% quarter-over-quarter.
  • 22 funds opened new Structure Therapeutics positions in Q3 2025 and 37 closed out, a net change of -15 holders.
  • The largest Structure Therapeutics buyer in Q3 2025 was Avoro Capital Advisors, an estimated $103M added.
  • The largest Structure Therapeutics seller in Q3 2025 was Capital International Investors, an estimated $33.6M sold.

Based on aggregated 13F filings for Q3 2025.